Mounjaro vs Zepbound

Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Regulators reviewed its efficacy in improving glycemic control, with studies showing HbA1c effect sizes for tirzepatide versus placebo ranging from -1.33 to -1.56 (Eli Lilly and Company — Mounjaro FDA Review (NDA215866, ORIG, p.96)) and versus insulin degludec ranging from -0.6 to -0.91 (Eli Lilly and Company — Mounjaro FDA Review (NDA215866, ORIG, p.95)).

Zepbound is indicated for obesity (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2 with at least one weight-related comorbid condition). Regulators also considered its use for moderate to severe obstructive sleep apnea (OSA) in adults with obesity. A key finding for Zepbound was a difference from placebo in AHI (LS Mean) of -23.8 (ELI LILLY AND CO — Zepbound (Autoinjector) FDA Review (NDA/B, p.140)) and a percent change from baseline in AHI of -56.2 (ELI LILLY AND CO — Zepbound (Autoinjector) FDA Review (NDA/B, p.142)).

The trials for Mounjaro and Zepbound differed significantly in their primary endpoints, patient populations, timepoints, and comparator arms. Mounjaro's trials focused on glycemic control in adults with type 2 diabetes, while Zepbound's trials investigated weight management and OSA in adults with obesity or overweight. The figures presented are from separate studies and should not be compared directly; neither drug is presented as superior based on these distinct trial outcomes.